Medical/Pharmaceuticals
Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development
CAMBRIDGE, Mass., Feb. 26, 2024 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting-edge technology innovations and providing a total solution from "Idea to IND" ("I to ITM"), announced today that it has entered into a collaboration agreement w...
2024-02-27 09:23
2429
Sengenics Corporation Announces Key Distributor in China
Sengenics Partners with Shanghai Universal Biotech Co., Ltd. (UniV) to Expand Reach of Immunoprofiling Products and Services inChina BOSTON, Feb. 27, 2024 /PRNewswire/ -- Sengenics Corporation LLC, a pioneer in the field of immunoproteomic biomarker discovery, proudly announces that it has enter...
2024-02-27 08:30
2860
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
SHANGHAI, China and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) approved Kezar's investig...
2024-02-27 07:14
3090
Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
MELBOURNE, Australia, Feb. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based inA...
2024-02-27 05:55
8930
Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases
* Collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases * Total potential deal value of $1.46B across multiple targets SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Neomorph, Inc. today announced it ...
2024-02-27 01:06
2817
BioCity Announces Enrollment Completion of the IgA Nephropathy (IgAN) Cohort in the Randomized, Placebo-controlled Phase II Clinical Trial of the ETA Receptor Antagonist SC0062
WUXI, China, Feb. 25, 2024 /PRNewswire/ -- BioCity Biopharma is pleased to announce the completion of enrollment of all 120 participants in the IgA nephropathy (IgAN) cohort in a randomized, double-blind, placebo-controlled Phase 2 clinical study of the novel, oral endothelin A (ETA)-receptor sel...
2024-02-26 22:38
1781
GC Cell and BioCentriq® Execute Process Transfer Agreement in Anticipation of the U.S. entry of Immuncell-LC Inj.
* Immuncell-LC Inj. is an autologous Cytokine Induced Killer (CIK) cell therapy approved for Commercial use inSouth Korea as an adjuvant cell therapy for the treatment of Hepatocellular Carcinoma (HCC) after curative resection and has receivedFDA Orphan Drug Designations (ODDs) for liver, brain...
2024-02-26 21:30
2301
OVER HALF OF AUSTRALIAN WOMEN FEEL THEIR PAIN IS IGNORED OR DISMISSED - HIGHLIGHTING NATIONAL GENDER PAIN GAP
* New research from Nurofen reveals a national Gender Pain Gap in Australia – with 55% of women feeling they have had their pain ignored or dismissed compared to just 48% of men1 * Significantly more women than men think the reason they haven't received a diagnosis for their pain or is taki...
2024-02-26 21:01
1943
TransThera initiates IND-Enabling studies for TT-02332, a novel, highly potent and CNS-penetrating NLRP3 inhibitor
NANJING, China and GAITHURSBURG, Md., Feb. 26, 2024 /PRNewswire/ -- TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced the initiation of IND-enabling studies for TT-02332, a potent, selective and highly CNS-penetrating NLR...
2024-02-26 21:00
1687
Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") launches MOTPOLY XR™ (lacosamide) extended-release capsules C-V, the first, and only once-daily formulation of lacosamide
PISCATAWAY, N.J., Feb. 26, 2024 /PRNewswire/ -- Aucta Pharmaceuticals, Inc., a private specialty pharmaceutical company focused on niche generic and branded specialty products, today announced the commercial launch of MOTPOLY XR (lacosamide) extended-release capsules C-V (100, 150 and 200 mg). M...
2024-02-26 21:00
1798
Waters Announces Seamless HPLC/UPLC Data Bridge for Light Scattering, Integrating Essential Instruments for Large Molecule Characterization
News Summary: * Waters now enables seamless connectivity between its liquid chromatography (LC) systems and multi-angle light-scattering instruments (MALS) for improved ease-of-use, efficiency, and data confidence in characterizing large molecules. * HPLC CONNECT™ software accelerates precise...
2024-02-26 21:00
2055
J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)
SEOUL, South Korea, Feb. 26, 2024 /PRNewswire/ -- J INTS BIO announced on the 26th of month that the Phase 1/2 clinical study of its Novel Oral 4th Generation EGFR TKI "JIN-A02" for the treatment of NSCLC has been accepted for poster presentation at the upcoming American Association for Cancer Re...
2024-02-26 16:15
1669
Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial
MELBOURNE, Australia, Feb. 26, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical...
2024-02-26 14:37
2832
Operation Smile and Beast Philanthropy Spotlight Global Need for Access to Surgical Care
VIRGINIA BEACH, Va., Feb. 25, 2024 /PRNewswire/ -- Global nonprofit Operation Smile today announced its partnership with Beast Philanthropy, the philanthropic arm of Mr. Beast that leverages the power of social media platforms to raise funds and leave a lasting impact. Operation Smile bridges th...
2024-02-26 10:10
1825
Siriraj Hospital Expands Services to Provide Advanced Medical Care, Highlights State-of-the-Art Technology for Cancer Treatment
BANGKOK, Feb. 26, 2024 /PRNewswire/ -- Cancer continues to be one of the major health crises globally and inThailand. Siriraj Hospital, recognized as one of the largest and leading hospitals inThailand, demonstrates its readiness and dedication to delivering comprehensive medical services, includ...
2024-02-26 08:00
2936
Cure Brain Cancer Foundation CEO Lance Kawaguchi Completes SouthPoleTrek4Cancer, Raises Over $1 Million for Cancer Research
SYDNEY, Feb. 26, 2024 /PRNewswire/ -- In an unprecedented feat of endurance and dedication to cancer research,Lance Kawaguchi, Chief Executive Officer of Cure Brain Cancer Foundation, successfully completed a challenging trek at the South Pole representing more than 20 charities across six countr...
2024-02-26 06:00
1747
Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024
WASHINGTON, Feb. 25, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, ...
2024-02-26 02:00
2377
China Medical University Hospital's Breakthrough: Leg Salvage Against Deadly Arterial Disease. Amputation and Death Rates Plunge from 30% to Below 3%
TAICHUNG, Feb. 24, 2024 /PRNewswire/ -- In winter, cardiovascular diseases are more prevalent, which significantly increase the likelihood of arterial blockage. In addition to increasing the possibility of accompanying myocardial infarction or stroke, seniors should be especially cautious about P...
2024-02-24 21:30
3019
China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
HAIKOU, China, Feb. 23, 2024 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-5 reverse stock split on its common stock effectiveWednesday, March 6, 2024, with trading to begin on a split-adjusted basi...
2024-02-24 05:05
5253
Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease
PANGYO, South Korea, Feb. 23, 2024 /PRNewswire/ -- Oscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of Alzheimer's disease (AD). Oscotec and ADEL are jointly developing a novel disease-modifying immunothera...
2024-02-23 21:00
2897
Week's Top Stories
Most Reposted
UFO SIM Launches in Australia, The Ultimate Travel eSIM Starting at Just AU$2/GB
[Picked up by 310 media titles]
2026-04-01 11:03
Sustainable Tourism Impact Fund Expands Investments Across Southeast Asia
[Picked up by 309 media titles]
2026-04-03 11:30
Surfin Meta Digital Technology signs MOU with the Philippine Social Security System to explore digital financial service enhancements
[Picked up by 307 media titles]
2026-04-01 09:00
Visa cements global K-pop connection as Worldwide Tour Sponsor for "BTS WORLD TOUR 'ARIRANG'"
[Picked up by 302 media titles]
2026-04-06 10:00
From Doomscroll to Page-Turner: BookXcess Launches The Brain Un-Rot Library to Help Rebuild a Generation's Focus
[Picked up by 302 media titles]
2026-03-31 13:53
Most Read
NYSE Content Update: Versigent To Ring Opening Bell As its Shares Debut for Trade
2026-04-01 22:44
5711
